Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase

被引：10

作者：

Bradshaw, D.

Malik, S.

Booth, C.

Van Houtte, M.

Pattery, T.

Waters, A.

Ainsworth, J.

Geretti, A. M.

机构：

[1] Royal Free Hosp, Dept Virol, London NW3 2QG, England

[2] UCL, Sch Med, Royal Free Hosp, London W1N 8AA, England

[3] Virco BVBA, Mechelen, Belgium

[4] N Middlesex Hosp, Dept HIV Med, London, England

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 12期

关键词：

D O I：

10.1128/AAC.00687-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.

引用

收藏

页码：4489 / 4491

页数：3

相关论文

共 10 条

[1] Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro [J].

Cherrington, JM ;

Mulato, AS ;

Fuller, MD ;

Chen, MS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2212-2216

[2] Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF [J].

Delaugerre, C ;

Roudiere, L ;

Peytavin, G ;

Rouzioux, C ;

Viard, JP ;

Chaix, ML .

JOURNAL OF CLINICAL VIROLOGY, 2005, 32 (03) :241-244

[3] In vitro selection and analysis of human immunodeficiency virus Type 1 resistant to derivatives of β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine [J].

Hammond, JL ;

Parikh, UM ;

Koontz, DL ;

Schlueter-Wirtz, S ;

Chu, CK ;

Bazmi, HZ ;

Schinazi, RF ;

Mellors, JW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3930-3932

[4]

Kagan R, 2005, ANTIVIR THER, V10, pS103

[5] Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 [J].

Margot, N. A. ;

Lu, B. ;

Cheng, A. ;

Miller, M. D. .

HIV MEDICINE, 2006, 7 (07) :442-450

[6] Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity [J].

Miller, MD ;

Lamy, PD ;

Fuller, MD ;

Mulato, AS ;

Margot, NA ;

Cihlar, T ;

Cherrington, JM .

MOLECULAR PHARMACOLOGY, 1998, 54 (02) :291-297

[7] Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy [J].

Mulato, AS ;

Lamy, PD ;

Miller, MD ;

Li, WX ;

Anton, KE ;

Hellmann, NS ;

Cherrington, JM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1620-1628

[8]

Roge BT, 2002, ANTIVIR THER, V7, pS165

[9]

Ross M G, 2001, J Matern Fetal Med, V10, P2, DOI 10.1080/714904292

[10] Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors [J].

Sluis-Cremer, Nicolas ;

Sheen, Chih-Wei ;

Zelina, Shannon ;

Torres, Pedro S. Argoti ;

Parikh, Urvi A. ;

Mellors, John W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) :48-53